EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro

Moises Dias iD, Luiz Felipe Pinto iD, Marcus Vinícius Pinto iD, Renata Gervais iD, Paula Accioli iD, Gabriela Amorim iD, Mariana Guedes iD, Carlos Perez Gomes iD, Roberto Coury Pedrosa iD, Márcia Waddington-Cruz iD

Arquivos de Neuro-Psiquiatria · 01.04.2024 · 82 (04) · 001-007

DOI: 10.1055/s-0044-1781463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arquivos de Neuro-Psiquiatria, erschienen am 01.04.2024. Verfasst von Moises Dias und 9 weiteren Autor:innen. Beteiligte Einrichtung: Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Serviço de Nefrologia, Rio de Janeiro RJ, Brazil. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Polyneuropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hereditary transthyretin amyloidosis (ATTRv) is an inherited, progressive, and fatal disease still largely underdiagnosed. Mutations in the transthyretin (TTR) gene cause the TTR protein to destabilize, misfold, aggregate, and deposit in body tissues, which makes ATTRv a disease with heterogeneous clinical phenotype.

Objective

To describe the long-term efficacy and safety of inotersen therapy in patients with ATTRv peripheral neuropathy (ATTRv-PN).

Methods

Patients who completed the NEURO-TTR pivotal study and the NEURO-TTR OLE open-label extension study migrated to the present study and were followed-up for at least 18 more months to an average of 67 months and up to 76 months since day 1 of the inotersen therapy (D1–first dose of inotersen). Disease progression was evaluated by standard measures.

Results

Ten ATTRv-PN patients with Val30Met mutation were included. The mean disease duration on D1 was of 3 years, and the mean age of the patients was of 46.8 years. During an additional 18-month follow up, neurological function, based on the Neuropathy Impairment Score and the Polyneuropathy Disability Score, functionality aspects (Karnofsky Performance Status), and nutritional and cardiac aspects were maintained. No new safety signs have been noted.

Conclusion

The treatment with inotersen was effective and well tolerated for the average of 67 months and up to 76 months. Our results are consistent with those of larger phase-III trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialPolyneuropathiesHumansMiddle AgedQuality of LifeBrazilOligonucleotides

Substanzen

InotersenOligonucleotides

Autor:innen und Institutionen

  • Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Serviço de Nefrologia, Rio de Janeiro RJ, Brazil.
  • Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Centro de Estudos em Paramiloidose Antônio Rodrigues de Mello (CEPARM), Rio de Janeiro RJ, Brazil.
  • Mayo Clinic, Department of Neurology, Rochester MN, United States.
  • Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Instituto de Cardiologia Edson Saad, Rio de Janeiro RJ, Brazil.
  • Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Programa de Pós-graduação/Centro de Estudos em Paramiloidose Antônio Rodrigues de Mello (CEPARM), Rio de Janeiro RJ, Brazil.

ORCID-Profile: Moises Dias, Luiz Felipe Pinto, Marcus Vinícius Pinto, Renata Gervais, Paula Accioli, Gabriela Amorim, Mariana Guedes, Carlos Perez Gomes, Roberto Coury Pedrosa, Márcia Waddington-Cruz

Zitieren

APA

Dias, M., Pinto, L. F., Pinto, M. V., Gervais, R., Accioli, P., Amorim, G., Guedes, M., Gomes, C. P., Pedrosa, R. C., & Waddington-Cruz, M. (2024). Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro. Arquivos de Neuro-Psiquiatria, 82(04), 001-007. https://doi.org/10.1055/s-0044-1781463

Vancouver

Dias M, Pinto LF, Pinto MV, Gervais R, Accioli P, Amorim G, et al. Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro. Arquivos de Neuro-Psiquiatria. 2024;82(04):001-007. doi:10.1055/s-0044-1781463

BibTeX
@article{Dias2024,
  author = {Dias, Moises and Pinto, Luiz Felipe and Pinto, Marcus Vinícius and Gervais, Renata and Accioli, Paula and Amorim, Gabriela and Guedes, Mariana and Gomes, Carlos Perez and Pedrosa, Roberto Coury and Waddington-Cruz, Márcia},
  title = {Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro},
  journal = {Arquivos de Neuro-Psiquiatria},
  year = {2024},
  volume = {82},
  number = {04},
  pages = {001--007},
  doi = {10.1055/s-0044-1781463}
}
Kostenlos starten →